Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

21 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Hypofractionation for Breast Cancer NCT01948726 - Eligibility Criteria

- 15/06/2019 - 1 Formulaire, 2 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01948726 Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible with less lung toxicity in smaller studies. Investigators initiated this multicenter phase II prospective trial to analyse acute toxicity of hypofractionation with simultaneous integrated boost in patients with early breast cancer under the hypothesis that the ratio of patients with acute radiogenic toxicity Grad II according NCI-CTCAE amounts maximum 20%.

Eligibility Breast Cancer NCT00897702

- 22/02/2017 - 1 Formulaire, 2 Groupes Item, 12 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00897702

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Radiotherapy; Local Surgery (Report Final and Annex Report 2 Final)

- 30/10/2020 - 1 Formulaire, 5 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Administrative, Radiotherapy, Radiotherapy , Local Surgery, Local Surgery
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

GBM Neurocognitive Evaluation Summary Form (CS) RTOG 0825 Phase III

- 09/01/2015 - 1 Formulaire, 6 Groupes Item, 39 Eléments de données, 1 Langue
Groupes Item: Header Module, Hopkins Verbal Learning Test - Revised Administration, Trail Making Test Part A, Trail Making Test Part B, Contolled Oral Word Association (COWA), Footer
RTOG 0825 Phase III GBM Neurocognitive Evaluation Summary Form (CS) Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5BE60D36-11E5-00FF-E044-0003BA3F9857

Brain and Central Nervous System Tumors NCT00304031 Treatment - RTOG-0525 T1: Radiotherapy Form - 2388768v1.0 - RTOG-0525 T1: Radiotherapy Form

- 09/01/2015 - 1 Formulaire, 1 Groupe Item, 20 Eléments de données, 1 Langue
Groupe Item: MODULE 1
RTOG-0525 T1: RadiotherapyForm Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FE14506D-7AFC-4C09-E034-0003BA3F9857

Breast Cancer Radiation Therapy Report NSABP B-36 NCT00087178 - Radiation Therapy Report Breast Cancer NCT00087178

- 20/05/2015 - 1 Formulaire, 4 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Header, Radiation therapy, Whole Breast Irradiation, Chest Wall Irradiation
NSABP Protocol B-36 Radiation Therapy Report Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer NCT00087178 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C87B5190-AA07-59CE-E034-0003BA12F5E7

Breast Cancer NCT01272037 Treatment - S1007 Radiation Therapy Form (S1007RAD) - 3139641v1.0 - S1007 Radiation Therapy Form (S1007RAD)

- 09/01/2015 - 1 Formulaire, 6 Groupes Item, 30 Eléments de données, 1 Langue
Groupes Item: Header Module, Radiation Therapy, Site Irradiated, Targeted Regions of Treatment, Partial Breast Irradiation Method, Comments
S1007 Radiation Therapy Form (S1007RAD) Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=90C9DFFB-2367-84DB-E040-BB89AD437DC2

Brain and Central Nervous System Tumors NCT00884741 Treatment - RTOG 0825 Phase III GBM Radiotherapy Form (T1) - 2796276v1.0 - RTOG 0825 Phase III GBM Radiotherapy Form (T1)

- 09/01/2015 - 1 Formulaire, 1 Groupe Item, 21 Eléments de données, 1 Langue
Groupe Item: Radiotherapy Form
RTOG 0825 Phase III GBM Radiotherapy Form (T1) Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5A7BC3C4-2306-2CB9-E044-0003BA3F9857

Radiation Therapy Reporting Form N0577

- 08/01/2015 - 1 Formulaire, 5 Groupes Item, 26 Eléments de données, 1 Langue
Groupes Item: Header Module, Brain, Technique, Treatment Areas, Dose and Time, Footer Module
North Central Cancer Treatment Group N0577 Radiation Therapy Reporting Form Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients With Newly Diagnosed Anaplastic Glioma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4C094A4D-BDDC-3997-E044-0003BA3F9857

E3F05 Radiation Therapy Form NCT00978458

- 16/06/2015 - 1 Formulaire, 6 Groupes Item, 24 Eléments de données, 1 Langue
Groupes Item: Header Module, Patient demographics, Vital Status, Therapy Administered, Non-Protocol Therapy, Comments
E3F05 Radiation Therapy Form NCT00978458 Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6C1889F9-D047-5474-E040-BB89AD431A23

Eligibility Prostate Cancer NCT00619515

- 10/06/2017 - 1 Formulaire, 1 Groupe Item, 21 Eléments de données, 1 Langue
Groupe Item: Criteria
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00619515

Hypofractionated Radiotherapy in Prostate Cancer NCT01368055 - Eligibility Criteria

- 15/03/2021 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01368055

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial